Examination of the Effect of Increasing Doses of Etoricoxib on Oral Methotrexate Pharmacokinetics in Patients With Rheumatoid Arthritis
| Autor: | Keith Gottesdiener, Jutta L. Miller, Thomas Marbury, Nancy G. B. Agrawal, Paul F. Cavanaugh, David Hoelscher, Jules I. Schwartz, Kenneth Bachmann, Peggy H. Wong |
|---|---|
| Rok vydání: | 2009 |
| Předmět: |
Adult
Male medicine.medical_specialty Pyridines Administration Oral Arthritis Gastroenterology Drug Administration Schedule Arthritis Rheumatoid Etoricoxib Pharmacokinetics Internal medicine medicine Humans Drug Interactions Pharmacology (medical) Sulfones Aged Pharmacology Cyclooxygenase 2 Inhibitors Dose-Response Relationship Drug business.industry Middle Aged medicine.disease Confidence interval Dose–response relationship Methotrexate Antirheumatic Agents Rheumatoid arthritis Anesthesia Toxicity Drug Therapy Combination Female business medicine.drug |
| Zdroj: | The Journal of Clinical Pharmacology. 49:1202-1209 |
| ISSN: | 0091-2700 |
| Popis: | The authors designed 2 randomized controlled studies to examine the effects of etoricoxib 60 to 120 mg daily on methotrexate pharmacokinetics in 50 rheumatoid arthritis (RA) patients on stable doses of methotrexate (7.5-20 mg). Patients received oral methotrexate at baseline and on days 7 and 14. In study 1, patients received etoricoxib 60 mg (days 1-7) and then 120 mg (days 8-14); in study 2, patients received etoricoxib 90 mg (days 1-7) and then 120 mg (days 8-14). For study 1, the AUC(0-infinity) geometric mean ratio (GMR) (90% confidence interval [CI]) for day 7 versus baseline was 1.01 (0.91, 1.12) for etoricoxib 60 mg; the area under the plasma concentration-time curve from zero to infinity (AUC(0-infinity)) GMR (90% CI) for day 14 was 1.28 (1.15, 1.42) for etoricoxib 120 mg. For study 2, the AUC(0-infinity) GMR (90% CI) for day 7 versus baseline was 1.07 (1.01, 1.13) for etoricoxib 90 mg; the AUC(0-infinity) GMR (90% CI) for day 14 was 1.05 (0.99, 1.11) for etoricoxib 120 mg. In summary, etoricoxib 60 and 90 mg had no effect on methotrexate plasma concentrations. Although no effect on methotrexate pharmacokinetics was observed with etoricoxib 120 mg in study 2, GMR AUC(0-infinity) fell outside the prespecified bounds in study 1. Standard monitoring of methotrexate-related toxicity should be continued when etoricoxib and methotrexate are administered concurrently, especially with doses >90 mg etoricoxib. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text